Analytical Data
-
基因名
EIF2aK3
- Application
-
别名
EIF2aK3；PEK；PERK；Eukaryotic translation initiation factor 2-alpha kinase 3
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NZJ5
-
表达区间
30-308aa
-
分子量
34.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
EIF2A kinase 3 (EIF2AK3), also known as PERK ( protein kinase RNA-like endoplasmic reticulum kinase), plays a crucial role in the cellular response to endoplasmic reticulum (ER) stress. This stress response is vital for maintaining cellular homeostasis and preventing apoptosis under unfavorable conditions. EIF2AK3 primarily regulates protein synthesis by phosphorylating the eukaryotic translation initiation factor 2 alpha (eIF2α), which leads to a decrease in global protein translation, allowing the cell to conserve resources and manage the accumulation of misfolded proteins within the ER. Dysfunction of EIF2AK3 has been implicated in various diseases, including diabetes, neurodegenerative disorders, and cancer, making it a significant target for therapeutic interventions. As a result, research into recombinant EIF2AK3 protein has gained momentum, focusing on its structural properties, mechanisms of action, and potential as a drug target. The ability to produce recombinant EIF2AK3 allows for detailed studies into its function and regulation, providing insights into its role in ER stress responses and the pathology of associated diseases. Understanding the dynamics of EIF2AK3 and its interaction with other signaling pathways could lead to novel strategies for enhancing cellular resilience or treating diseases linked to ER dysfunction.
